ReviewInnere Medizin (Heidelberg, Germany)2026
[Myelofibrosis: watch and wait or treat?]
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelofibrosis (MF) is a rare clonal disease of the haematopoietic stem cell characterised by pathological activation of the JAK/STAT signalling pathway. The disease typically manifests clinically as anaemia, splenomegaly and constitutional symptoms. The therapeutic decision between watchful waiting and active treatment is based primarily on the risk profile, symptoms and molecular genetic findings. While low-risk patients without symptoms can be monitored, those at higher risk or with significant symptoms benefit from early treatment, especially with Janus kinase (JAK) inhibitors. Ruxolitinib has been the standard of care since 2012, and newer substances such as momelotinib are expanding the spectrum, especially in anaemic patients. For suitable patients, allogeneic stem cell transplantation remains the only curative option. Future developments are aimed at personalised, disease-modifying therapy that goes beyond mere symptom control.
Indexed as
Identifiers
41329342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.